This Market Spotlight report covers the uterine cancer market, comprising key pipeline drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals.
- The report estimates that in 2016, there were 335,200 incident cases of uterine cancer in females worldwide, and expects that number to increase to 367,300 incident cases by 2025.
- Incidence rates are highest in Northern America and Europe, and lowest in Latin America and the Caribbean, while the number of incident cases is highest in Asia. The majority of industry-sponsored drugs in active clinical development for uterine cancer are in Phase II. Therapies in the pipeline for uterine cancer focus on a variety of targets. The vast majority of pipeline drugs in development are administered orally, with one drug being tested in an intravenous formulation. There were three licensing and asset acquisition activities involving endometrial cancer drugs during 2012-17. The largest deal during that time was the March 2016 $1,119m exclusive licensing agreement between Exelixis and Ipsen, for cabozantinib's commercialization and further development.
- The clinical trials distribution across Phases I-IV indicates that the majority of trials for uterine neoplasms have been in early and mid-phases of development, with 96.4% of trials in Phase I-II and only 3.6% in Phase III-IV.
- The US has a substantial lead in the number of uterine neoplasms clinical trials globally, while Germany leads the major EU markets.
- Clinical trial activity in the uterine neoplasms space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for uterine neoplasms, with six.
- Sanofi leads industry sponsors with the highest number of clinical trials for uterine neoplasms, followed by AstraZeneca, Eli Lilly, and Merck & Co.
Key Topics Covered:
- Key Takeaways
- Disease Background
- Pipeline Drugs
- Licensing And Asset Acquisition Deals
- Parent Patents
- Clinical Trial Landscape
For more information about this report visit https://www.researchandmarkets.com/research/w327hl/uterine_cancer?w=4